AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice-Reference-Cited by-同舟云学术

AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice

Published:2019-03 Issue: Volume:12 Page:85-101
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Colella Pasqualina,Sellier Pauline,Costa Verdera Helena,Puzzo Francesco,van Wittenberghe Laetitia,Guerchet Nicolas,Daniele Nathalie,Gjata Bernard,Marmier Solenne,Charles Severine,Simon Sola Marcelo,Ragone Isabella,Leborgne Christian,Collaud Fanny,Mingozzi Federico

Funder

Genethon

French Muscular Dystrophy Association

European Union Research and Innovation Program

European Research Council

ASTRE Laboratories of the Essonne General Council

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference95 articles.

1. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial;Russell;Lancet,2017